Canaccord Genuity Group Inc.

CF.TO·Toronto·Financial Services
Compare
13.49−0.13 (−0.95%)today
At close: Oct 23, 4:00 PM EDT · May be delayed up to 15 min · CAD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close13.62
Open13.62
Day range13.3313.64
52-week range10.6515.55
Off day high−1.10%
Off 52-week high−13.25%
Volume99.45K
Avg. volume (3M)191.24K
Market cap1.38B
EPS (TTM)-1.06
Forward P/E9.50
P/E ratio (TTM)—
Dividend yield2.94% (0.4000)
Beta (5Y)1.66
Shares outstanding102.00M
Short interest—
Earnings dateAug 6, 2026
Analyst target17.83
Profit margin−4.21%

Against its peers

Compare in full ›
CF.TO CANG INVP.L BGC CS0.F 1776.HK
Market cap 1.38B 74.66M 3.73B 5.50B 9.15B 125.75B
P/E (TTM) — — 7.9 29.5 6.6 6.3
Forward P/E 9.5 -13.0 6.1 7.4 — 6.7
Price/book 2.4 0.6 0.9 5.0 0.8 0.8
Dividend yield 2.94% — 6.50% 0.67% 3.48% 5.52%
1-year change +15.13% −91.14% +1.63% +26.09% −21.77% −18.28%
Today −0.95% −23.21% +0.59% −0.84% +2.61% +2.68%

The closest companies by business and industry (Capital Markets). Prices may be delayed up to 15 min.

Latest news

All CF.TO news ›
The Globe and Mail·Negative

Canaccord Genuity Sticks to Their Buy Rating for Incyte (INCY)

In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Incyte, with a price target of $152.00. According to TipRanks, Newman is an analyst with an average return of -2.8% and a 39.11% success rate. Newman…

markets.businessinsider.com·Positive

Canaccord Genuity Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating on Voyager Therapeutics yesterday and set a price target of $12.00. The company’s shares closed yesterday at $3.20. Kulkarni covers the Healthcare sector, focusing on stocks…

Markets Daily·Positive

Afentra (LON:AET) Given “Buy” Rating at Canaccord Genuity Group

Afentra (LON:AET – Get Free Report)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a report issued on Wednesday, Digital Look reports. They presently have a GBX 135 price objective on the stock. Canaccord Genuity…

markets.businessinsider.com·Negative

Canaccord Genuity Keeps Their Buy Rating on Actinogen Medical (ATGGF)

In a report released yesterday, Shane Storey from Canaccord Genuity maintained a Buy rating on Actinogen Medical , with a price target of A$0.08. According to TipRanks, Storey is a 3-star analyst with an average return of 2.2% and a 46.88%…

From articles in the 4Search news index.

In the news

74mentions in 30 days
73with it in the headline
Positivesentiment

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 74 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.